Abstract
The KDOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease,1 Section 11.2, states “To assess aluminum exposure and the risk of aluminum toxicity, serum aluminum levels should be measured at least yearly and every 3 months in those receiving aluminum-containing medications. (OPINION)” This recommendation was amended in the more recent pediatric guidelines2 to include only patients with stage 5 chronic kidney disease. The accompanying text briefly explains the history and risks of aluminum toxicity as demonstrated primarily in dialysis patients during the past 30 years.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
